Phase III KEYNOTE-426: Updated Analysis of First-line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced RCC

May 29-31, 2020; Online at
After nearly 2 years of follow-up, pembrolizumab plus axitinib provides durable improvements in OS and PFS as compared with sunitinib in treatment-naive patients with advanced RCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 329 KB
Released: June 2, 2020


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Pfizer and EMD Serono, Inc.

Related Content

Gain key clinical insights fast, with this short slideset from CCO on biomarkers for imuno-onolcogy approaches across solid tumors

Jamie E. Chaft, MD John L. Marshall, MD Scot Niglio, MD Released: July 15, 2020

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

In this slideset from Clinical Care Options, Scot Niglio, MD provides insights on the latest data on immunotherapy approaches for bladder cancer, RCC, and prostate cancer.

Scot Niglio, MD Released: July 9, 2020

Gain key clinical insights fast, with this short slideset from CCO on the optimal use of immune checkpoint inhibitors for RCC

M. Dror Michaelson, MD, PhD Robert Motzer, MD Released: July 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?